{"id":"epirubicin-cyclophosphamide-paclitaxel-carboplatin-pembrolizumab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Rash"},{"rate":"10-30%","effect":"Hypertension"},{"rate":"5-20%","effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Epirubicin, cyclophosphamide, paclitaxel, and carboplatin work by targeting rapidly dividing cancer cells. Epirubicin and cyclophosphamide induce DNA damage, while paclitaxel prevents cell division. Carboplatin also induces DNA damage. Pembrolizumab enhances the body's immune response against cancer cells by blocking the PD-1 receptor, allowing T-cells to attack cancer cells more effectively.","oneSentence":"Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis in cancer cells. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division. Carboplatin is a platinum-based alkylating agent that cross-links DNA, causing cell death. Pembrolizumab is a monoclonal antibody that blocks PD-1, enhancing T-cell mediated immune response against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:09.117Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Advanced ovarian cancer"},{"name":"Non-small cell lung cancer"},{"name":"Triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06831955","phase":"PHASE2","title":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-02-01","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting","enrollment":356},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT06802757","phase":"PHASE2","title":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-01","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT06829199","phase":"PHASE2","title":"A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-26","conditions":"Early Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT07016399","phase":"PHASE2","title":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","status":"RECRUITING","sponsor":"Vandana Abramson","startDate":"2025-09-09","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma","enrollment":51},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT04335669","phase":"PHASE3","title":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lund University Hospital","startDate":"2019-12-20","conditions":"Breast Cancer, Triple Negative Breast Neoplasms","enrollment":325},{"nctId":"NCT06371807","phase":"PHASE2","title":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"Fundacao Champalimaud","startDate":"2024-07","conditions":"Early Breast Cancer, Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT05763992","phase":"PHASE2","title":"Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2023-05-15","conditions":"Breast Cancer, Triple Negative Breast Cancer, Dietary Exposure","enrollment":145}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["anthracycline, taxane, platinum"],"phase":"phase_3","status":"active","brandName":"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab","genericName":"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab","companyName":"Lund University Hospital","companyId":"lund-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis in cancer cells. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division. Carboplatin is a platinum-based alkylating agent that cross-links DNA, causing cell death. Pembrolizumab is a monoclonal antibody that blocks PD-1, enhancing T-cell mediated immune response against cancer cells. Used for Metastatic breast cancer, Advanced ovarian cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}